The Utility of Salivary Cortisone in the Overnight Dexamethasone Suppression Test in Adrenal Incidentalomas
The Journal of Clinical Endocrinology & Metabolism · 18.09.2023 · 108 (10) · e937-e943
DOI: 10.1210/clinem/dgad242 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.05.2023. Verfasst von Basil George Issa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, Manchester University NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Cortisone, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Context
Guidelines recommend the assessment of cortisol secretion in patients with adrenal incidentalomas (AI) using the overnight dexamethasone suppression test (ONDST). This requires attendance at a health care facility and venepuncture. Alternatively, the ONDST can be done by measuring salivary cortisol and cortisone, which can be collected at home.
Objective
We aimed to assess the utility of these measurements in patients with AI.
Methods
A retrospective analysis of data from 173 patients with AI who underwent an ONDST and salivary cortisol/cortisone diurnal studies. Serum and salivary cortisol and salivary cortisone were collected at 09:00, late night, and at 09:00 the following morning after dexamethasone. Dexamethasone levels were measured in the postdexamethasone samples. Serum and salivary samples were analyzed with liquid chromatography–tandem mass spectrometry.
Results
We identified a strong correlation between salivary cortisone and serum cortisol after 1 mg of dexamethasone (r = 0.95). Stepwise multivariate regression showed that postdexamethasone salivary cortisone, baseline serum cortisol, salivary cortisone suppression (predexamethasone/postdexamethasone ratio), and sex were the only significant or near-significant independent variables. Performance of predictive indices using these 4 parameters (sensitivity = 88.5%, specificity = 91.2%; kappa 0.80) and postdexamethasone salivary cortisone alone (sensitivity = 85.3%, specificity = 91.7%; kappa 0.77) were comparable when used to predict an ONDST serum cortisol of ≤50 nmol/L. No correlation was observed with any of the other measured parameters.
Conclusion
In AI patients, after dexamethasone, salivary cortisone correlates very strongly with serum cortisol in the ONDST and could therefore be used as an alternative sampling method which does not require venepuncture or attendance at hospital.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Diabetes, Manchester University NHS Foundation Trust, Manchester, UK.
- Department of Endocrinology and Diabetes, University Hospitals of North Staffordshire NHS Trust, Stoke-on-Trent, UK.
- Impact Accelerator Unit, School of Medicine, Keele University, Staffordshire, UK.
- Department of Clinical Biochemistry, Manchester University Foundation Trust, Manchester, UK.
ORCID-Profile: Basil George Issa, Anthony A Fryer
Zitieren
APA
Issa, B. G., Hanna, F. W. F., Fryer, A. A., Ensah, G., Ebere, I., Marshall, D., & Keevil, B. (2023). The Utility of Salivary Cortisone in the Overnight Dexamethasone Suppression Test in Adrenal Incidentalomas. The Journal of Clinical Endocrinology & Metabolism, 108(10), e937-e943. https://doi.org/10.1210/clinem/dgad242
Vancouver
Issa BG, Hanna FWF, Fryer AA, Ensah G, Ebere I, Marshall D, et al. The Utility of Salivary Cortisone in the Overnight Dexamethasone Suppression Test in Adrenal Incidentalomas. The Journal of Clinical Endocrinology & Metabolism. 2023;108(10):e937-e943. doi:10.1210/clinem/dgad242
BibTeX
@article{Issa2023,
author = {Issa, Basil George and Hanna, Fahmy W F and Fryer, Anthony A and Ensah, Grace and Ebere, Ikenna and Marshall, David and Keevil, Brian},
title = {The Utility of Salivary Cortisone in the Overnight Dexamethasone Suppression Test in Adrenal Incidentalomas},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {10},
pages = {e937--e943},
doi = {10.1210/clinem/dgad242}
}
EUVIMED